Gerald Preston

Array ( [id] => 4024317 [patent_doc_number] => 05925729 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-07-20 [patent_title] => 'Tumor rejection antigen precursors, tumor rejection antigens and uses thereof' [patent_app_type] => 1 [patent_app_number] => 8/142368 [patent_app_country] => US [patent_app_date] => 1994-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 15 [patent_no_of_words] => 22566 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/925/05925729.pdf [firstpage_image] =>[orig_patent_app_number] => 142368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3881722 [patent_doc_number] => 05723128 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-03-03 [patent_title] => 'Cytotoxic T-cell lymphocyte (\"CTL\") activity regulation by class I MHC peptides' [patent_app_type] => 1 [patent_app_number] => 8/222851 [patent_app_country] => US [patent_app_date] => 1994-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 15 [patent_no_of_words] => 18912 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/723/05723128.pdf [firstpage_image] =>[orig_patent_app_number] => 222851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3659799 [patent_doc_number] => 05656488 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-08-12 [patent_title] => 'Recombinant avirulent salmonella antifertility vaccines' [patent_app_type] => 1 [patent_app_number] => 8/222182 [patent_app_country] => US [patent_app_date] => 1994-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 23 [patent_no_of_words] => 27547 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/656/05656488.pdf [firstpage_image] =>[orig_patent_app_number] => 222182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3864140 [patent_doc_number] => 05762937 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-06-09 [patent_title] => 'Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus' [patent_app_type] => 1 [patent_app_number] => 8/219816 [patent_app_country] => US [patent_app_date] => 1994-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 1 [patent_no_of_words] => 14171 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/762/05762937.pdf [firstpage_image] =>[orig_patent_app_number] => 219816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3591187 [patent_doc_number] => 05585461 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1996-12-17 [patent_title] => 'Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof' [patent_app_type] => 1 [patent_app_number] => 8/217186 [patent_app_country] => US [patent_app_date] => 1994-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 4034 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/585/05585461.pdf [firstpage_image] =>[orig_patent_app_number] => 217186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3543087 [patent_doc_number] => 05554506 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1996-09-10 [patent_title] => 'Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof' [patent_app_type] => 1 [patent_app_number] => 8/217187 [patent_app_country] => US [patent_app_date] => 1994-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3742 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/554/05554506.pdf [firstpage_image] =>[orig_patent_app_number] => 217187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3546350 [patent_doc_number] => 05554724 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1996-09-10 [patent_title] => 'Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof' [patent_app_type] => 1 [patent_app_number] => 8/217188 [patent_app_country] => US [patent_app_date] => 1994-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 8310 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/554/05554724.pdf [firstpage_image] =>[orig_patent_app_number] => 217188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3777687 [patent_doc_number] => 05820866 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-10-13 [patent_title] => 'Product and process for T cell regulation' [patent_app_type] => 1 [patent_app_number] => 8/207481 [patent_app_country] => US [patent_app_date] => 1994-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 17682 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 20 [patent_words_short_claim] => 186 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/820/05820866.pdf [firstpage_image] =>[orig_patent_app_number] => 207481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4150505 [patent_doc_number] => 06113903 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-09-05 [patent_title] => 'Peptides and methods against diabetes' [patent_app_type] => 1 [patent_app_number] => 8/195963 [patent_app_country] => US [patent_app_date] => 1994-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 7338 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/113/06113903.pdf [firstpage_image] =>[orig_patent_app_number] => 195963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3597100 [patent_doc_number] => 05558995 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1996-09-24 [patent_title] => 'Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof' [patent_app_type] => 1 [patent_app_number] => 8/195186 [patent_app_country] => US [patent_app_date] => 1994-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3062 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/558/05558995.pdf [firstpage_image] =>[orig_patent_app_number] => 195186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3622387 [patent_doc_number] => 05612216 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-03-18 [patent_title] => 'Nucleotide sequence encoding intercellular adhesion molecule-1 and fragments thereof' [patent_app_type] => 1 [patent_app_number] => 8/186456 [patent_app_country] => US [patent_app_date] => 1994-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 33 [patent_no_of_words] => 45966 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/612/05612216.pdf [firstpage_image] =>[orig_patent_app_number] => 186456 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3619401 [patent_doc_number] => 05614409 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-03-25 [patent_title] => 'Production of IBDV VP2 in highly immunogenic form' [patent_app_type] => 1 [patent_app_number] => 8/182402 [patent_app_country] => US [patent_app_date] => 1994-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 14 [patent_no_of_words] => 11212 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/614/05614409.pdf [firstpage_image] =>[orig_patent_app_number] => 182402 [rel_patent_id] =>[rel_patent_doc_number] =>)